1
|
Hughes K, Jacobson CEH, Lavelle G, Carr E, Henley SMD. The Association of Resilience with Psychosocial Outcomes in Teenagers and Young Adults with Cancer. J Adolesc Young Adult Oncol 2024; 13:331-337. [PMID: 37643298 DOI: 10.1089/jayao.2022.0159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/31/2023] Open
Abstract
Purpose: There is limited research on the psychological impact of cancer for teenagers and young adults (TYAs) and the role of protective factors such as resilience. This study investigated associations between resilience and psychosocial outcomes in this group. Methods: Data were collected from TYAs (aged 16-24) who attended the TYA cancer clinic at Guy's Hospital between 2013 and 2021. Participants (N = 63) completed psychosocial questionnaires within 4 weeks of their treatment start date (T1) and again between 9 and 15 months later (T2). We used separate multivariable linear regression models to analyze associations of resilience (Brief Resilience Questionnaire) with outcomes measured at T2, including symptoms of depression (Patient Health Questionnaire [PHQ]-9), anxiety (Generalized Anxiety Disorder [GAD]-7), and subjective quality of life. Models were adjusted for age, gender, ethnicity, and T1 outcome assessments. Results: Higher resilience at T1 was associated with increased anxiety (β = 1.68; bootstrapped confidence interval [95% CI -0.28 to 3.19]), depression (β = 1.24; [-0.85 to 2.90]), and quality of life (5.76; [-0.88 to 15.60]). In contrast, an increase in resilience over time was associated with decreases in the same period in anxiety (β = -3.16; [-5.22 to -1.47]) and depression (β = -2.36, [-4.41 to -0.58]), and an increase in quality of life (β = 9.82, [-0.24 to 21.13]). Conclusion: Increases in resilience during cancer treatment were associated with reduced symptoms of depression and anxiety in TYAs. We discuss factors likely to influence these outcomes, the implications for psychosocial interventions in this population, and identify further research to explore the impact of other factors such as diagnosis and treatment type.
Collapse
Affiliation(s)
- Kathryn Hughes
- Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
- South London and Maudsley NHS Foundation Trust, London, United Kingdom
| | | | - Grace Lavelle
- Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Ewan Carr
- Department of Biostatistics and Health Informatics, King's College London, London, United Kingdom
| | - Susie M D Henley
- Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
- Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
| |
Collapse
|
2
|
Hughes K, Blackett L, Jacobson CEH, Henley SMD, Carr E. A Systematic Review of the Psychosocial Measures Used in Teenage and Young Adult Cancer. J Adolesc Young Adult Oncol 2024; 13:30-39. [PMID: 37477895 DOI: 10.1089/jayao.2023.0051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/22/2023] Open
Abstract
Background: Teenagers and young adults (TYAs; ages 16-24 in the United Kingdom) with cancer have specific needs and experience worse physiological and psychological outcomes compared with pediatric and adult cancer. In the United Kingdom, psychosocial screening is a mandatory part of TYA care. However, there is a lack of age-appropriate and acceptable psychosocial measures for this population. This review aimed to (1) identify the psychosocial measures utilized and available for TYA cancer and (2) describe their psychometric properties. Methods: We searched five databases for studies meeting the eligibility criteria. We extracted data relevant to the review and assessed study quality using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guidelines and the Hughes Quality Assessment Tool developed by the research team. Results: We identified 40 studies that included 105 psychosocial measures. The main constructs measured were distress, depression, and anxiety. The TYA age range varied widely. Reporting of psychosocial measures and their psychometric properties was poor, and most measures were not validated or developed for TYA cancer populations. Discussion: There is an urgent need for psychosocial measures that are designed for and validated in TYA cancer populations. Appropriate measures would enable clinicians to reliably identify and effectively support the psychosocial challenges faced by TYAs. The use of validated psychosocial measures enables earlier detection of difficulties, fosters patient-centered care, and is cost-effective since resources can be allocated to those most in need.
Collapse
Affiliation(s)
- Kathryn Hughes
- Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
- South London and Maudsley NHS Foundation Trust, London, United Kingdom
| | - Laura Blackett
- Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
- South London and Maudsley NHS Foundation Trust, London, United Kingdom
| | | | - Susie M D Henley
- Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
- Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
| | - Ewan Carr
- Department of Biostatistics and Health Informatics, King's College London, London, United Kingdom
| |
Collapse
|
3
|
Collins JD, Henley SMD, Suárez-González A. A systematic review of the prevalence of depression, anxiety, and apathy in frontotemporal dementia, atypical and young-onset Alzheimer's disease, and inherited dementia. Int Psychogeriatr 2023; 35:457-476. [PMID: 32684177 DOI: 10.1017/s1041610220001118] [Citation(s) in RCA: 20] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVES Depression, anxiety, and apathy are the most commonly reported neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD). Understanding their prevalence in rarer dementias such as frontotemporal dementia (FTD), primary progressive aphasia (PPA), posterior cortical atrophy (PCA), young-onset AD (YOAD), and inherited dementias has implications for both clinical practice and research. In this study, we aimed to examine the current state of knowledge of the prevalence of these three NPS in less prevalent dementias. DESIGN We conducted a systematic review based on searches of EMBASE, PsycINFO, and PubMed up to September 2019. RESULTS 47 articles meeting inclusion criteria were identified. Depression, anxiety, and apathy were commonly reported across the phenotypes studied but their prevalence showed large variation between studies. Apathy showed the highest reported frequency in FTD (50-100% across studies), behavioral variant frontotemporal dementia (bvFTD) (73-100%), and YOAD (44-100%). Anxiety was frequently reported in FTD (0-100%) and bvFTD (19-63%). Depression showed the highest prevalence in FTD (7-69%) and YOAD (11-55%). Among the three variants of PPA, sv-PPA is the one most investigated (seven articles). Three or fewer articles were identified examining NPS in the remaining PPA variants, PCA, familial AD, and familial FTD. Inconsistency in the tools used to measure symptoms and small sample sizes were common methodological limitations. CONCLUSIONS Future studies should consider the inclusion of larger sample sizes (e.g. through multicenter collaborations) and the use of harmonized protocols that include the combination of caregiver and patient-derived measures and symptom-specific questionnaires. More research is needed on the phenotype-specific barriers and facilitators for people living with dementia to successfully engage in self-reports of NPS.
Collapse
Affiliation(s)
- Jessica D Collins
- Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, University College London, London, UK
| | - Susie M D Henley
- Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, University College London, London, UK
| | - Aida Suárez-González
- Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, University College London, London, UK
| |
Collapse
|
4
|
Lu K, Yong KXX, Skorupinska I, Deriziotis S, Collins JD, Henley SMD, Hanna MG, Rossor MN, Ridha BH, Machado PM. A cross-sectional study of memory and executive functions in patients with sporadic inclusion body myositis. Muscle Nerve 2022; 65:105-109. [PMID: 34605039 DOI: 10.1002/mus.27426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 09/22/2021] [Accepted: 09/28/2021] [Indexed: 11/07/2022]
Abstract
INTRODUCTION/AIMS Sporadic inclusion body myositis (IBM) is a degenerative and inflammatory acquired myopathy characterized by muscle deposition of various proteins typically associated with Alzheimer disease and other neurodegenerative diseases. Although cognitive impairment is not noted as a clinical feature of IBM, evidence is lacking. In this study we investigated whether cognitive performance of patients with IBM differs from population norms, focusing on cognitive domains affected in early Alzheimer disease (memory, executive function), and to test whether disease duration and the level of disability of IBM are associated with cognitive function. METHODS Twenty-four patients with IBM (mean [standard deviation]: age, 62.0 [7.2] years; disease duration, 9.6 [4.8] years) were assessed cross-sectionally on neuropsychological tests covering multiple cognitive domains, including the Preclinical Alzheimer Cognitive Composite (PACC). Performance was compared with published normative data adjusted for age, sex, and education (National Alzheimer's Coordinating Center; N = 3268). Associations were examined between PACC score, disease duration, and level of disability (assessed using the IBM Functional Rating Scale [IBMFRS]). RESULTS Across all cognitive tests, group performance was within ±1 standard deviation of the normative mean. There was no evidence of associations between PACC score and either disease duration (ρ = -0.04, P = .87) or IBMFRS total score (ρ = 0.14, P = .52). DISCUSSION Memory and executive function in patients with IBM did not differ from normative data, and we observed no evidence of associations between the cognitive composite and disease duration or level of disability. This addresses a question frequently asked by patients and will be of value for clinicians and patients alike.
Collapse
Affiliation(s)
- Kirsty Lu
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Keir X X Yong
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Iwona Skorupinska
- Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, University College Hospitals NHS Foundation Trust, London, UK
| | - Stephanie Deriziotis
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Jessica D Collins
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Susie M D Henley
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Michael G Hanna
- Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, University College Hospitals NHS Foundation Trust, London, UK
- NIHR University College London Hospitals Biomedical Research Centre, London, UK
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Martin N Rossor
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
- NIHR University College London Hospitals Biomedical Research Centre, London, UK
| | - Basil H Ridha
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
- NIHR University College London Hospitals Biomedical Research Centre, London, UK
| | - Pedro M Machado
- Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, University College Hospitals NHS Foundation Trust, London, UK
- NIHR University College London Hospitals Biomedical Research Centre, London, UK
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK
- Centre for Rheumatology, Division of Medicine, University College London, London, UK
| |
Collapse
|
5
|
Lu K, Nicholas JM, Weston PSJ, Stout JC, O’Regan AM, James SN, Buchanan SM, Lane CA, Parker TD, Keuss SE, Keshavan A, Murray-Smith H, Cash DM, Sudre CH, Malone IB, Coath W, Wong A, Richards M, Henley SMD, Fox NC, Schott JM, Crutch SJ. Visuomotor integration deficits are common to familial and sporadic preclinical Alzheimer's disease. Brain Commun 2021; 3:fcab003. [PMID: 33615219 PMCID: PMC7882207 DOI: 10.1093/braincomms/fcab003] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Revised: 12/04/2020] [Accepted: 12/08/2020] [Indexed: 11/26/2022] Open
Abstract
We investigated whether subtle visuomotor deficits were detectable in familial and sporadic preclinical Alzheimer's disease. A circle-tracing task-with direct and indirect visual feedback, and dual-task subtraction-was completed by 31 individuals at 50% risk of familial Alzheimer's disease (19 presymptomatic mutation carriers; 12 non-carriers) and 390 cognitively normal older adults (members of the British 1946 Birth Cohort, all born during the same week; age range at assessment = 69-71 years), who also underwent β-amyloid-PET/MRI to derive amyloid status (positive/negative), whole-brain volume and white matter hyperintensity volume. We compared preclinical Alzheimer's groups against controls cross-sectionally (mutation carriers versus non-carriers; amyloid-positive versus amyloid-negative) on speed and accuracy of circle-tracing and subtraction. Mutation carriers (mean 7 years before expected onset) and amyloid-positive older adults traced disproportionately less accurately than controls when visual feedback was indirect, and were slower at dual-task subtraction. In the older adults, the same pattern of associations was found when considering amyloid burden as a continuous variable (Standardized Uptake Value Ratio). The effect of amyloid was independent of white matter hyperintensity and brain volumes, which themselves were associated with different aspects of performance: greater white matter hyperintensity volume was also associated with disproportionately poorer tracing accuracy when visual feedback was indirect, whereas larger brain volume was associated with faster tracing and faster subtraction. Mutation carriers also showed evidence of poorer tracing accuracy when visual feedback was direct. This study provides the first evidence of visuomotor integration deficits common to familial and sporadic preclinical Alzheimer's disease, which may precede the onset of clinical symptoms by several years.
Collapse
Affiliation(s)
- Kirsty Lu
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| | - Jennifer M Nicholas
- Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK
| | - Philip S J Weston
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| | - Julie C Stout
- Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia
| | - Alison M O’Regan
- Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia
| | - Sarah-Naomi James
- MRC Unit for Lifelong Health and Ageing at UCL, London, WC1E 7HB, UK
| | - Sarah M Buchanan
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| | - Christopher A Lane
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| | - Thomas D Parker
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| | - Sarah E Keuss
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| | - Ashvini Keshavan
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| | - Heidi Murray-Smith
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| | - David M Cash
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
- UK Dementia Research Institute at University College London, London, UK
| | - Carole H Sudre
- MRC Unit for Lifelong Health and Ageing at UCL, London, WC1E 7HB, UK
- School of Biomedical Engineering and Imaging Sciences, King’s College London, London, SE1 7EU, UK
- Department of Medical Physics, University College London, London, WC1E 7JE, UK
| | - Ian B Malone
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| | - William Coath
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| | - Andrew Wong
- MRC Unit for Lifelong Health and Ageing at UCL, London, WC1E 7HB, UK
| | - Marcus Richards
- MRC Unit for Lifelong Health and Ageing at UCL, London, WC1E 7HB, UK
| | - Susie M D Henley
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| | - Nick C Fox
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
- UK Dementia Research Institute at University College London, London, UK
| | - Jonathan M Schott
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| | - Sebastian J Crutch
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK
| |
Collapse
|
6
|
Lu K, Nicholas JM, Collins JD, James SN, Parker TD, Lane CA, Keshavan A, Keuss SE, Buchanan SM, Murray-Smith H, Cash DM, Sudre CH, Malone IB, Coath W, Wong A, Henley SMD, Crutch SJ, Fox NC, Richards M, Schott JM. Cognition at age 70: Life course predictors and associations with brain pathologies. Neurology 2019; 93:e2144-e2156. [PMID: 31666352 PMCID: PMC6937487 DOI: 10.1212/wnl.0000000000008534] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Accepted: 06/12/2019] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVE To investigate predictors of performance on a range of cognitive measures including the Preclinical Alzheimer Cognitive Composite (PACC) and test for associations between cognition and dementia biomarkers in Insight 46, a substudy of the Medical Research Council National Survey of Health and Development. METHODS A total of 502 individuals born in the same week in 1946 underwent cognitive assessment at age 69-71 years, including an adapted version of the PACC and a test of nonverbal reasoning. Performance was characterized with respect to sex, childhood cognitive ability, education, and socioeconomic position (SEP). In a subsample of 406 cognitively normal participants, associations were investigated between cognition and β-amyloid (Aβ) positivity (determined from Aβ-PET imaging), whole brain volumes, white matter hyperintensity volumes (WMHV), and APOE ε4. RESULTS Childhood cognitive ability was strongly associated with cognitive scores including the PACC more than 60 years later, and there were independent effects of education and SEP. Sex differences were observed on every PACC subtest. In cognitively normal participants, Aβ positivity and WMHV were independently associated with lower PACC scores, and Aβ positivity was associated with poorer nonverbal reasoning. Aβ positivity and WMHV were not associated with sex, childhood cognitive ability, education, or SEP. Normative data for 339 cognitively normal Aβ-negative participants are provided. CONCLUSIONS This study adds to emerging evidence that subtle cognitive differences associated with Aβ deposition are detectable in older adults, at an age when dementia prevalence is very low. The independent associations of childhood cognitive ability, education, and SEP with cognitive performance at age 70 have implications for interpretation of cognitive data in later life.
Collapse
Affiliation(s)
- Kirsty Lu
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK.
| | - Jennifer M Nicholas
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Jessica D Collins
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Sarah-Naomi James
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Thomas D Parker
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Christopher A Lane
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Ashvini Keshavan
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Sarah E Keuss
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Sarah M Buchanan
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Heidi Murray-Smith
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - David M Cash
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Carole H Sudre
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Ian B Malone
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - William Coath
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Andrew Wong
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Susie M D Henley
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Sebastian J Crutch
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Nick C Fox
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Marcus Richards
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK
| | - Jonathan M Schott
- From the Dementia Research Centre (K.L., J.D.C., T.D.P., C.A.L., A.K., S.E.K., S.M.B., H.M.-S., D.M.C., C.H.S., I.B.M., W.C., S.M.D.H., S.J.C., N.C.F., J.M.S.), UCL Queen Square Institute of Neurology, University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine; MRC Unit for Lifelong Health and Ageing at UCL (S.-N.J., A.W., M.R.); and School of Biomedical Engineering and Imaging Sciences (D.M.C., C.H.S.), King's College London, UK.
| |
Collapse
|
7
|
Weston PSJ, Nicholas JM, Henley SMD, Liang Y, Macpherson K, Donnachie E, Schott JM, Rossor MN, Crutch SJ, Butler CR, Zeman AZ, Fox NC. Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol 2019; 17:123-132. [PMID: 29413314 PMCID: PMC5958413 DOI: 10.1016/s1474-4422(17)30434-9] [Citation(s) in RCA: 68] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Revised: 11/13/2017] [Accepted: 11/14/2017] [Indexed: 12/22/2022]
Abstract
Background Tests sensitive to presymptomatic changes in Alzheimer's disease could be valuable for clinical trials. Accelerated long-term forgetting—during which memory impairment becomes apparent over longer periods than usually assessed, despite normal performance on standard cognitive testing—has been identified in other temporal lobe disorders. We assessed whether accelerated long-term forgetting is a feature of presymptomatic autosomal dominant (familial) Alzheimer's disease, and whether there is an association between accelerated long-term forgetting and early subjective memory changes. Methods This was a cross-sectional study at the Dementia Research Centre, University College London (London, UK). Participants were recruited from a cohort of autosomal dominant Alzheimer's disease families already involved in research at University College London, and had to have a parent known to be affected by an autosomal dominant Alzheimer's disease mutation, and not report any current symptoms of cognitive decline. Accelerated long-term forgetting of three tasks (list, story, and figure recall) was assessed by comparing 7-day recall with initial learning and 30-min recall. 7-day recognition was also assessed. Subjective memory was assessed using the Everyday Memory Questionnaire. The primary outcome measure for each task was the proportion of material retained at 30 min that was recalled 7 days later (ie, 7-day recall divided by 30-min recall). We used linear regression to compare accelerated long-term forgetting scores between mutation carriers and non-carriers (adjusting for age, IQ, and test set) and, for mutation carriers, to assess whether there was an association between accelerated long-term forgetting and estimated years to symptom onset (EYO). Spearman's correlation was used to examine the association between accelerated long-term forgetting and subjective memory scores. Findings Between Feb 17, 2015 and March 30, 2016, we recruited 35 people. 21 participants were mutation carriers (mean EYO 7·2 years, SD 4·5). Across the three tasks, we detected no differences between carriers and non-carriers for initial learning or 30-min recall. The proportion of material recalled at 7 days was lower in carriers than non-carriers for list (estimated difference in mean for list recall −30·94 percentage points, 95% CI −45·16 to −16·73; p=0·0002), story (–20·10, −33·28 to −6·91; p=0·0048), and figure (–15·41, −26·88 to −3·93; p=0·012) recall. Accelerated long-term forgetting was greater in carriers nearer to their estimated age at onset (p≤0·01 for all three tests). Mutation carriers' 7-day recognition memory was also lower across all tasks (list [mean difference −5·80, 95% CI −9·96 to −2·47; p<0·01], story [–6·84, −10·94 to −3·37; p<0·01], and figure [–17·61, −27·68 to −7·72; p<0·01] recognition). Subjective memory scores were poorer in asymptomatic carriers compared with non-carriers (adjusted difference in means 7·88, 95% CI 1·36 to 14·41; p=0·016), and we found a correlation between accelerated long-term forgetting and subjective memory in mutation carriers. Interpretation Accelerated long-term forgetting is an early presymptomatic feature of autosomal dominant Alzheimer's disease, which appears to pre-date other amnestic deficits and might underpin subjective memory complaints in Alzheimer's disease. Accelerated long-term forgetting testing might be useful in presymptomatic Alzheimer's disease trials. Funding MRC, NIHR, Alzheimer's Research UK, Dementias Platform UK, Dunhill Medical Trust, ERUK, Great Western Research, Health Foundation, Patrick Berthoud Trust.
Collapse
Affiliation(s)
- Philip S J Weston
- Dementia Research Centre, University College London Institute of Neurology, London, UK
| | | | - Susie M D Henley
- Dementia Research Centre, University College London Institute of Neurology, London, UK
| | - Yuying Liang
- Dementia Research Centre, University College London Institute of Neurology, London, UK
| | - Kirsty Macpherson
- Dementia Research Centre, University College London Institute of Neurology, London, UK
| | - Elizabeth Donnachie
- Dementia Research Centre, University College London Institute of Neurology, London, UK
| | - Jonathan M Schott
- Dementia Research Centre, University College London Institute of Neurology, London, UK
| | - Martin N Rossor
- Dementia Research Centre, University College London Institute of Neurology, London, UK
| | - Sebastian J Crutch
- Dementia Research Centre, University College London Institute of Neurology, London, UK
| | - Christopher R Butler
- Memory Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Adam Z Zeman
- Cognitive Neurology Research Group, University of Exeter Medical School, Exeter, UK
| | - Nick C Fox
- Dementia Research Centre, University College London Institute of Neurology, London, UK.
| |
Collapse
|
8
|
Slattery CF, Zhang J, Paterson RW, Foulkes AJM, Carton A, Macpherson K, Mancini L, Thomas DL, Modat M, Toussaint N, Cash DM, Thornton JS, Henley SMD, Crutch SJ, Alexander DC, Ourselin S, Fox NC, Zhang H, Schott JM. ApoE influences regional white-matter axonal density loss in Alzheimer's disease. Neurobiol Aging 2017; 57:8-17. [PMID: 28578156 PMCID: PMC5538347 DOI: 10.1016/j.neurobiolaging.2017.04.021] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2016] [Revised: 04/14/2017] [Accepted: 04/22/2017] [Indexed: 01/10/2023]
Abstract
Mechanisms underlying phenotypic heterogeneity in young onset Alzheimer disease (YOAD) are poorly understood. We used diffusion tensor imaging and neurite orientation dispersion and density imaging (NODDI) with tract-based spatial statistics to investigate apolipoprotein (APOE) ε4 modulation of white-matter damage in 37 patients with YOAD (22, 59% APOE ε4 positive) and 23 age-matched controls. Correlation between neurite density index (NDI) and neuropsychological performance was assessed in 4 white-matter regions of interest. White-matter disruption was more widespread in ε4+ individuals but more focal (posterior predominant) in the absence of an ε4 allele. NODDI metrics indicate fractional anisotropy changes are underpinned by combinations of axonal loss and morphological change. Regional NDI in parieto-occipital white matter correlated with visual object and spatial perception battery performance (right and left, both p = 0.02), and performance (nonverbal) intelligence (WASI matrices, right, p = 0.04). NODDI provides tissue-specific microstructural metrics of white-matter tract damage in YOAD, including NDI which correlates with focal cognitive deficits, and APOEε4 status is associated with different patterns of white-matter neurodegeneration.
Collapse
Affiliation(s)
- Catherine F Slattery
- Department of Neurodegenerative Disease, Institute of Neurology, UCL, London, UK.
| | - Jiaying Zhang
- Department of Computer Science and Centre for Medical Image Computing, UCL, London, UK
| | - Ross W Paterson
- Department of Neurodegenerative Disease, Institute of Neurology, UCL, London, UK
| | | | - Amelia Carton
- Department of Neurodegenerative Disease, Institute of Neurology, UCL, London, UK
| | - Kirsty Macpherson
- Department of Neurodegenerative Disease, Institute of Neurology, UCL, London, UK
| | - Laura Mancini
- Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, London, UK; Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, UK
| | - David L Thomas
- Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, London, UK; Leonard Wolfson Experimental Neurology Centre, UCL Institute of Neurology, London, UK
| | - Marc Modat
- Translational Imaging Group, Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, UCL, London, UK
| | - Nicolas Toussaint
- Translational Imaging Group, Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, UCL, London, UK
| | - David M Cash
- Department of Neurodegenerative Disease, Institute of Neurology, UCL, London, UK; Translational Imaging Group, Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, UCL, London, UK
| | - John S Thornton
- Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, London, UK; Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, UK
| | - Susie M D Henley
- Department of Neurodegenerative Disease, Institute of Neurology, UCL, London, UK
| | - Sebastian J Crutch
- Department of Neurodegenerative Disease, Institute of Neurology, UCL, London, UK
| | - Daniel C Alexander
- Department of Computer Science and Centre for Medical Image Computing, UCL, London, UK
| | - Sebastien Ourselin
- Translational Imaging Group, Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, UCL, London, UK
| | - Nick C Fox
- Department of Neurodegenerative Disease, Institute of Neurology, UCL, London, UK
| | - Hui Zhang
- Department of Computer Science and Centre for Medical Image Computing, UCL, London, UK
| | - Jonathan M Schott
- Department of Neurodegenerative Disease, Institute of Neurology, UCL, London, UK
| |
Collapse
|
9
|
Lane CA, Parker TD, Cash DM, Macpherson K, Donnachie E, Murray-Smith H, Barnes A, Barker S, Beasley DG, Bras J, Brown D, Burgos N, Byford M, Jorge Cardoso M, Carvalho A, Collins J, De Vita E, Dickson JC, Epie N, Espak M, Henley SMD, Hoskote C, Hutel M, Klimova J, Malone IB, Markiewicz P, Melbourne A, Modat M, Schrag A, Shah S, Sharma N, Sudre CH, Thomas DL, Wong A, Zhang H, Hardy J, Zetterberg H, Ourselin S, Crutch SJ, Kuh D, Richards M, Fox NC, Schott JM. Study protocol: Insight 46 - a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurol 2017; 17:75. [PMID: 28420323 PMCID: PMC5395844 DOI: 10.1186/s12883-017-0846-x] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2017] [Accepted: 03/21/2017] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Increasing age is the biggest risk factor for dementia, of which Alzheimer's disease is the commonest cause. The pathological changes underpinning Alzheimer's disease are thought to develop at least a decade prior to the onset of symptoms. Molecular positron emission tomography and multi-modal magnetic resonance imaging allow key pathological processes underpinning cognitive impairment - including β-amyloid depostion, vascular disease, network breakdown and atrophy - to be assessed repeatedly and non-invasively. This enables potential determinants of dementia to be delineated earlier, and therefore opens a pre-symptomatic window where intervention may prevent the onset of cognitive symptoms. METHODS/DESIGN This paper outlines the clinical, cognitive and imaging protocol of "Insight 46", a neuroscience sub-study of the MRC National Survey of Health and Development. This is one of the oldest British birth cohort studies and has followed 5362 individuals since their birth in England, Scotland and Wales during one week in March 1946. These individuals have been tracked in 24 waves of data collection incorporating a wide range of health and functional measures, including repeat measures of cognitive function. Now aged 71 years, a small fraction have overt dementia, but estimates suggest that ~1/3 of individuals in this age group may be in the preclinical stages of Alzheimer's disease. Insight 46 is recruiting 500 study members selected at random from those who attended a clinical visit at 60-64 years and on whom relevant lifecourse data are available. We describe the sub-study design and protocol which involves a prospective two time-point (0, 24 month) data collection covering clinical, neuropsychological, β-amyloid positron emission tomography and magnetic resonance imaging, biomarker and genetic information. Data collection started in 2015 (age 69) and aims to be completed in 2019 (age 73). DISCUSSION Through the integration of data on the socioeconomic environment and on physical, psychological and cognitive function from 0 to 69 years, coupled with genetics, structural and molecular imaging, and intensive cognitive and neurological phenotyping, Insight 46 aims to identify lifetime factors which influence brain health and cognitive ageing, with particular focus on Alzheimer's disease and cerebrovascular disease. This will provide an evidence base for the rational design of disease-modifying trials.
Collapse
Affiliation(s)
- Christopher A. Lane
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | - Thomas D. Parker
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | - Dave M. Cash
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - Kirsty Macpherson
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | - Elizabeth Donnachie
- Leonard Wolfson Experimental Neurology Centre, Institute of Neurology, University College London, London, UK
| | - Heidi Murray-Smith
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | - Anna Barnes
- Institute of Nuclear Medicine, University College London Hospitals, London, UK
| | - Suzie Barker
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | - Daniel G. Beasley
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - Jose Bras
- Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK
- Department of Medical Sciences and Institute of Biomedicine - iBiMED, University of Aveiro, Aveiro, Portugal
| | - David Brown
- Institute of Nuclear Medicine, University College London Hospitals, London, UK
| | - Ninon Burgos
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | | | - M. Jorge Cardoso
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - Ana Carvalho
- Institute of Nuclear Medicine, University College London Hospitals, London, UK
| | - Jessica Collins
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | - Enrico De Vita
- Lysholm Department of Neuroradiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
- Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, Institute of Neurology, University College London, London, UK
| | - John C. Dickson
- Institute of Nuclear Medicine, University College London Hospitals, London, UK
| | - Norah Epie
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | - Miklos Espak
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - Susie M. D. Henley
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | - Chandrashekar Hoskote
- Lysholm Department of Neuroradiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
| | - Michael Hutel
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - Jana Klimova
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | - Ian B. Malone
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | - Pawel Markiewicz
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - Andrew Melbourne
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - Marc Modat
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - Anette Schrag
- Department of Clinical Neuroscience, Institute of Neurology, University College London, London, UK
| | - Sachit Shah
- Lysholm Department of Neuroradiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
- Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, Institute of Neurology, University College London, London, UK
| | - Nikhil Sharma
- MRC Unit for Lifelong Health and Ageing at UCL, London, UK
- National Hospital for Neurology and Neurosurgery, London, UK
| | - Carole H. Sudre
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - David L. Thomas
- Leonard Wolfson Experimental Neurology Centre, Institute of Neurology, University College London, London, UK
- Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, Institute of Neurology, University College London, London, UK
| | - Andrew Wong
- MRC Unit for Lifelong Health and Ageing at UCL, London, UK
| | - Hui Zhang
- Department of Computer Science and Centre for Medical Image Computing, University College London, London, UK
| | - John Hardy
- Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK
| | - Henrik Zetterberg
- Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Sebastien Ourselin
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - Sebastian J. Crutch
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | - Diana Kuh
- MRC Unit for Lifelong Health and Ageing at UCL, London, UK
| | | | - Nick C. Fox
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | - Jonathan M. Schott
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| |
Collapse
|
10
|
Liang Y, Pertzov Y, Nicholas JM, Henley SMD, Crutch S, Woodward F, Husain M. Visual short-term memory binding deficits in Alzheimer's disease: a reply to Parra's commentary. Cortex 2016; 88:201-204. [PMID: 27979314 DOI: 10.1016/j.cortex.2016.11.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2016] [Revised: 11/04/2016] [Accepted: 11/04/2016] [Indexed: 11/16/2022]
Affiliation(s)
- Yuying Liang
- Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK
| | - Yoni Pertzov
- Department of Psychology, The Hebrew University of Jerusalem, Israel
| | - Jennifer M Nicholas
- Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
| | - Susie M D Henley
- Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK
| | - Sebastian Crutch
- Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK
| | - Felix Woodward
- Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK
| | - Masud Husain
- Nuffield Department of Clinical Neuroscience, University of Oxford, UK; Department of Experimental Psychology, University of Oxford, UK.
| |
Collapse
|
11
|
Liang Y, Pertzov Y, Nicholas JM, Henley SMD, Crutch S, Woodward F, Leung K, Fox NC, Husain M. Visual short-term memory binding deficit in familial Alzheimer's disease. Cortex 2016; 78:150-164. [PMID: 27085491 PMCID: PMC4865502 DOI: 10.1016/j.cortex.2016.01.015] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2015] [Revised: 11/20/2015] [Accepted: 01/27/2016] [Indexed: 01/31/2023]
Abstract
Long-term episodic memory deficits in Alzheimer's disease (AD) are well characterised but, until recently, short-term memory (STM) function has attracted far less attention. We employed a recently-developed, delayed reproduction task which requires participants to reproduce precisely the remembered location of items they had seen only seconds previously. This paradigm provides not only a continuous measure of localization error in memory, but also an index of relational binding by determining the frequency with which an object is misplaced to the location of one of the other items held in memory. Such binding errors in STM have previously been found on this task to be sensitive to medial temporal lobe (MTL) damage in focal lesion cases. Twenty individuals with pathological mutations in presenilin 1 or amyloid precursor protein genes for familial Alzheimer's disease (FAD) were tested together with 62 healthy controls. Participants were assessed using the delayed reproduction memory task, a standard neuropsychological battery and structural MRI. Overall, FAD mutation carriers were worse than controls for object identity as well as in gross localization memory performance. Moreover, they showed greater misbinding of object identity and location than healthy controls. Thus they would often mislocalize a correctly-identified item to the location of one of the other items held in memory. Significantly, asymptomatic gene carriers - who performed similarly to healthy controls on standard neuropsychological tests - had a specific impairment in object-location binding, despite intact memory for object identity and location. Consistent with the hypothesis that the hippocampus is critically involved in relational binding regardless of memory duration, decreased hippocampal volume across FAD participants was significantly associated with deficits in object-location binding but not with recall precision for object identity or localization. Object-location binding may therefore provide a sensitive cognitive biomarker for MTL dysfunction in a range of diseases including AD.
Collapse
Affiliation(s)
- Yuying Liang
- Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK.
| | - Yoni Pertzov
- Department of Psychology, The Hebrew University of Jerusalem, Israel.
| | - Jennifer M Nicholas
- Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
| | - Susie M D Henley
- Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK.
| | - Sebastian Crutch
- Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK.
| | - Felix Woodward
- Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK.
| | - Kelvin Leung
- Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK.
| | - Nick C Fox
- Dementia Research Centre, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK.
| | - Masud Husain
- Nuffield Department of Clinical Neurosciences, University of Oxford, UK; Department of Experimental Psychology, University of Oxford, UK.
| |
Collapse
|
12
|
Clark CN, Nicholas JM, Henley SMD, Downey LE, Woollacott IO, Golden HL, Fletcher PD, Mummery CJ, Schott JM, Rohrer JD, Crutch SJ, Warren JD. Humour processing in frontotemporal lobar degeneration: A behavioural and neuroanatomical analysis. Cortex 2015; 69:47-59. [PMID: 25973788 PMCID: PMC4534772 DOI: 10.1016/j.cortex.2015.03.024] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Revised: 03/04/2015] [Accepted: 03/29/2015] [Indexed: 12/13/2022]
Abstract
Humour is a complex cognitive and emotional construct that is vulnerable in neurodegenerative diseases, notably the frontotemporal lobar degenerations. However, humour processing in these diseases has been little studied. Here we assessed humour processing in patients with behavioural variant frontotemporal dementia (n = 22, mean age 67 years, four female) and semantic dementia (n = 11, mean age 67 years, five female) relative to healthy individuals (n = 21, mean age 66 years, 11 female), using a joint cognitive and neuroanatomical approach. We created a novel neuropsychological test requiring a decision about the humorous intent of nonverbal cartoons, in which we manipulated orthogonally humour content and familiarity of depicted scenarios. Structural neuroanatomical correlates of humour detection were assessed using voxel-based morphometry. Assessing performance in a signal detection framework and after adjusting for standard measures of cognitive function, both patient groups showed impaired accuracy of humour detection in familiar and novel scenarios relative to healthy older controls (p < .001). Patient groups showed similar overall performance profiles; however the behavioural variant frontotemporal dementia group alone showed a significant advantage for detection of humour in familiar relative to novel scenarios (p = .045), suggesting that the behavioural variant syndrome may lead to particular difficulty decoding novel situations for humour, while semantic dementia produces a more general deficit of humour detection that extends to stock comedic situations. Humour detection accuracy was associated with grey matter volume in a distributed network including temporo-parietal junctional and anterior superior temporal cortices, with predominantly left-sided correlates of processing humour in familiar scenarios and right-sided correlates of processing novel humour. The findings quantify deficits of core cognitive operations underpinning humour processing in frontotemporal lobar degenerations and suggest a candidate brain substrate in cortical hub regions processing incongruity and semantic associations. Humour is a promising candidate tool with which to assess complex social signal processing in neurodegenerative disease.
Collapse
Affiliation(s)
- Camilla N Clark
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom
| | - Jennifer M Nicholas
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom; London School of Hygiene and Tropical Medicine, University of London, London, United Kingdom
| | - Susie M D Henley
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom
| | - Laura E Downey
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom
| | - Ione O Woollacott
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom
| | - Hannah L Golden
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom
| | - Phillip D Fletcher
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom
| | - Catherine J Mummery
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom
| | - Jonathan M Schott
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom
| | - Jonathan D Rohrer
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom
| | - Sebastian J Crutch
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom
| | - Jason D Warren
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, United Kingdom.
| |
Collapse
|
13
|
Yong KXX, Shakespeare TJ, Cash D, Henley SMD, Nicholas JM, Ridgway GR, Golden HL, Warrington EK, Carton AM, Kaski D, Schott JM, Warren JD, Crutch SJ. Prominent effects and neural correlates of visual crowding in a neurodegenerative disease population. ACTA ACUST UNITED AC 2014; 137:3284-99. [PMID: 25351740 PMCID: PMC4240300 DOI: 10.1093/brain/awu293] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Crowding is a breakdown in the ability to identify objects in clutter, and is a major constraint on object recognition. Crowding particularly impairs object perception in peripheral, amblyopic and possibly developing vision. Here we argue that crowding is also a critical factor limiting object perception in central vision of individuals with neurodegeneration of the occipital cortices. In the current study, individuals with posterior cortical atrophy (n=26), typical Alzheimer's disease (n=17) and healthy control subjects (n=14) completed centrally-presented tests of letter identification under six different flanking conditions (unflanked, and with letter, shape, number, same polarity and reverse polarity flankers) with two different target-flanker spacings (condensed, spaced). Patients with posterior cortical atrophy were significantly less accurate and slower to identify targets in the condensed than spaced condition even when the target letters were surrounded by flankers of a different category. Importantly, this spacing effect was observed for same, but not reverse, polarity flankers. The difference in accuracy between spaced and condensed stimuli was significantly associated with lower grey matter volume in the right collateral sulcus, in a region lying between the fusiform and lingual gyri. Detailed error analysis also revealed that similarity between the error response and the averaged target and flanker stimuli (but not individual target or flanker stimuli) was a significant predictor of error rate, more consistent with averaging than substitution accounts of crowding. Our findings suggest that crowding in posterior cortical atrophy can be regarded as a pre-attentive process that uses averaging to regularize the pathologically noisy representation of letter feature position in central vision. These results also help to clarify the cortical localization of feature integration components of crowding. More broadly, we suggest that posterior cortical atrophy provides a neurodegenerative disease model for exploring the basis of crowding. These data have significant implications for patients with, or who will go on to develop, dementia-related visual impairment, in whom acquired excessive crowding likely contributes to deficits in word, object, face and scene perception.
Collapse
Affiliation(s)
- Keir X X Yong
- 1 Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, UK
| | - Timothy J Shakespeare
- 1 Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, UK
| | - Dave Cash
- 1 Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, UK 2 Centre for Medical Image Computing, University College London, UK
| | - Susie M D Henley
- 1 Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, UK 3 University College London Hospitals NHS Foundation Trust, London, UK
| | - Jennifer M Nicholas
- 1 Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, UK 4 Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, England, UK
| | - Gerard R Ridgway
- 5 Wellcome Trust Centre for Neuroimaging, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK 6 Centre for Functional MRI of the Brain, University of Oxford, Oxford, UK
| | - Hannah L Golden
- 1 Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, UK
| | - Elizabeth K Warrington
- 1 Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, UK
| | - Amelia M Carton
- 1 Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, UK
| | - Diego Kaski
- 7 Division of Brain Sciences, Imperial College London, Charing Cross Hospital, London, UK
| | - Jonathan M Schott
- 1 Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, UK
| | - Jason D Warren
- 1 Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, UK
| | - Sebastian J Crutch
- 1 Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, UK
| |
Collapse
|
14
|
Henley SMD, Downey LE, Nicholas JM, Kinnunen KM, Golden HL, Buckley A, Mahoney CJ, Crutch SJ. Degradation of cognitive timing mechanisms in behavioural variant frontotemporal dementia. Neuropsychologia 2014; 65:88-101. [PMID: 25447066 PMCID: PMC4410788 DOI: 10.1016/j.neuropsychologia.2014.10.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Accepted: 10/07/2014] [Indexed: 12/01/2022]
Abstract
The current study examined motor timing in frontotemporal dementia (FTD), which manifests as progressive deterioration in social, behavioural and cognitive functions. Twenty-patients fulfilling consensus clinical criteria for behavioural variant FTD (bvFTD), 11 patients fulfilling consensus clinical criteria for semantic-variant primary progressive aphasia (svPPA), four patients fulfilling criteria for nonfluent/agrammatic primary progressive aphasia (naPPA), eight patients fulfilling criteria for Alzheimer׳s disease (AD), and 31 controls were assessed on both an externally- and self-paced finger-tapping task requiring maintenance of a regular, 1500 ms beat over 50 taps. Grey and white matter correlates of deficits in motor timing were examined using voxel-based morphometry (VBM) and diffusion tensor imaging (DTI). bvFTD patients exhibited significant deficits in aspects of both externally- and self-paced tapping. Increased mean inter-response interval (faster than target tap time) in the self-paced task was associated with reduced grey matter volume in the cerebellum bilaterally, right middle temporal gyrus, and with increased axial diffusivity in the right superior longitudinal fasciculus, regions and tracts which have been suggested to be involved in a subcortical–cortical network of structures underlying timing abilities. This suggests that such structures can be affected in bvFTD, and that impaired motor timing may underlie some characteristics of the bvFTD phenotype. We examine motor timing in behavioural variant FTD. Patients with behavioural variant FTD showed impaired motor timing. Patients tended to tap faster than target and speed up during the task. Faster tapping was associated with reduced grey matter in the cerebellum. Impaired timing might underlie some other behavioural features of FTD.
Collapse
Affiliation(s)
- Susie M D Henley
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London WC1N 3BG, United Kingdom; National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, Queens Square, London WC1N 3BG, United Kingdom.
| | - Laura E Downey
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London WC1N 3BG, United Kingdom.
| | - Jennifer M Nicholas
- Department of Medical Statistics, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom.
| | - Kirsi M Kinnunen
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London WC1N 3BG, United Kingdom.
| | - Hannah L Golden
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London WC1N 3BG, United Kingdom.
| | - Aisling Buckley
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London WC1N 3BG, United Kingdom.
| | - Colin J Mahoney
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London WC1N 3BG, United Kingdom.
| | - Sebastian J Crutch
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London WC1N 3BG, United Kingdom.
| |
Collapse
|
15
|
Yong KXX, Shakespeare TJ, Cash D, Henley SMD, Warren JD, Crutch SJ. (Con)text-specific effects of visual dysfunction on reading in posterior cortical atrophy. Cortex 2014; 57:92-106. [PMID: 24841985 PMCID: PMC4194349 DOI: 10.1016/j.cortex.2014.03.010] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Revised: 02/14/2014] [Accepted: 03/28/2014] [Indexed: 11/13/2022]
Abstract
Reading deficits are a common early feature of the degenerative syndrome posterior cortical atrophy (PCA) but are poorly understood even at the single word level. The current study evaluated the reading accuracy and speed of 26 PCA patients, 17 typical Alzheimer's disease (tAD) patients and 14 healthy controls on a corpus of 192 single words in which the following perceptual properties were manipulated systematically: inter-letter spacing, font size, length, font type, case and confusability. PCA reading was significantly less accurate and slower than tAD patients and controls, with performance significantly adversely affected by increased letter spacing, size, length and font (cursive < non-cursive), and characterised by visual errors (69% of all error responses). By contrast, tAD and control accuracy rates were at or near ceiling, letter spacing was the only perceptual factor to influence reading speed in the same direction as controls, and, in contrast to PCA patients, control reading was faster for larger font sizes. The inverse size effect in PCA (less accurate reading of large than small font size print) was associated with lower grey matter volume in the right superior parietal lobule. Reading accuracy was associated with impairments of early visual (especially crowding), visuoperceptual and visuospatial processes. However, these deficits were not causally related to a universal impairment of reading as some patients showed preserved reading for small, unspaced words despite grave visual deficits. Rather, the impact of specific types of visual dysfunction on reading was found to be (con)text specific, being particularly evident for large, spaced, lengthy words. These findings improve the characterisation of dyslexia in PCA, shed light on the causative and associative factors, and provide clear direction for the development of reading aids and strategies to maximise and sustain reading ability in the early stages of disease.
Collapse
Affiliation(s)
- Keir X X Yong
- Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, London, UK.
| | - Timothy J Shakespeare
- Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, London, UK
| | - Dave Cash
- Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, London, UK
| | - Susie M D Henley
- Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, London, UK
| | - Jason D Warren
- Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, London, UK
| | - Sebastian J Crutch
- Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, University College London, London, UK
| |
Collapse
|
16
|
Rees EM, Hobbs NZ, Farmer RE, Henley SMD, Haider S, Scahill RI, Tabrizi SJ. J09 Cognitive functions of the putamen in Huntington's disease. J Neurol Neurosurg Psychiatry 2012. [DOI: 10.1136/jnnp-2012-303524.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
17
|
Novak MJU, Warren JD, Henley SMD, Draganski B, Frackowiak RS, Tabrizi SJ. Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease. ACTA ACUST UNITED AC 2012; 135:1165-79. [PMID: 22505631 PMCID: PMC3326253 DOI: 10.1093/brain/aws024] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
Huntington's disease is an inherited neurodegenerative disease that causes motor, cognitive and psychiatric impairment, including an early decline in ability to recognize emotional states in others. The pathophysiology underlying the earliest manifestations of the disease is not fully understood; the objective of our study was to clarify this. We used functional magnetic resonance imaging to investigate changes in brain mechanisms of emotion recognition in pre-manifest carriers of the abnormal Huntington's disease gene (subjects with pre-manifest Huntington's disease): 16 subjects with pre-manifest Huntington's disease and 14 control subjects underwent 1.5 tesla magnetic resonance scanning while viewing pictures of facial expressions from the Ekman and Friesen series. Disgust, anger and happiness were chosen as emotions of interest. Disgust is the emotion in which recognition deficits have most commonly been detected in Huntington's disease; anger is the emotion in which impaired recognition was detected in the largest behavioural study of emotion recognition in pre-manifest Huntington's disease to date; and happiness is a positive emotion to contrast with disgust and anger. Ekman facial expressions were also used to quantify emotion recognition accuracy outside the scanner and structural magnetic resonance imaging with voxel-based morphometry was used to assess the relationship between emotion recognition accuracy and regional grey matter volume. Emotion processing in pre-manifest Huntington's disease was associated with reduced neural activity for all three emotions in partially separable functional networks. Furthermore, the Huntington's disease-associated modulation of disgust and happiness processing was negatively correlated with genetic markers of pre-manifest disease progression in distributed, largely extrastriatal networks. The modulated disgust network included insulae, cingulate cortices, pre- and postcentral gyri, precunei, cunei, bilateral putamena, right pallidum, right thalamus, cerebellum, middle frontal, middle occipital, right superior and left inferior temporal gyri, and left superior parietal lobule. The modulated happiness network included postcentral gyri, left caudate, right cingulate cortex, right superior and inferior parietal lobules, and right superior frontal, middle temporal, middle occipital and precentral gyri. These effects were not driven merely by striatal dysfunction. We did not find equivalent associations between brain structure and emotion recognition, and the pre-manifest Huntington's disease cohort did not have a behavioural deficit in out-of-scanner emotion recognition relative to controls. In addition, we found increased neural activity in the pre-manifest subjects in response to all three emotions in frontal regions, predominantly in the middle frontal gyri. Overall, these findings suggest that pathophysiological effects of Huntington's disease may precede the development of overt clinical symptoms and detectable cerebral atrophy.
Collapse
Affiliation(s)
- Marianne J U Novak
- Wellcome Trust Centre for Neuroimaging, University College London Institute of Neurology, Queen Square, London WC1N 3BG, UK
| | | | | | | | | | | |
Collapse
|
18
|
Scahill RI, Hobbs NZ, Say MJ, Bechtel N, Henley SMD, Hyare H, Langbehn DR, Jones R, Leavitt BR, Roos RAC, Durr A, Johnson H, Lehéricy S, Craufurd D, Kennard C, Hicks SL, Stout JC, Reilmann R, Tabrizi SJ. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp 2011; 34:519-29. [PMID: 22102212 DOI: 10.1002/hbm.21449] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2010] [Revised: 07/19/2010] [Accepted: 08/08/2010] [Indexed: 11/06/2022] Open
Abstract
TRACK-HD is a multicentre longitudinal observational study investigating the use of clinical assessments and 3-Tesla magnetic resonance imaging as potential biomarkers for future therapeutic trials in Huntington's disease (HD). The cross-sectional data from this large well-characterized dataset provide the opportunity to improve our knowledge of how the underlying neuropathology of HD may contribute to the clinical manifestations of the disease across the spectrum of premanifest (PreHD) and early HD. Two hundred and thirty nine gene-positive subjects (120 PreHD and 119 early HD) from the TRACK-HD study were included. Using voxel-based morphometry (VBM), grey and white matter volumes were correlated with performance in four domains: quantitative motor (tongue force, metronome tapping, and gait); oculomotor [anti-saccade error rate (ASE)]; cognition (negative emotion recognition, spot the change and the University of Pennsylvania smell identification test) and neuropsychiatric measures (apathy, affect and irritability). After adjusting for estimated disease severity, regionally specific associations between structural loss and task performance were found (familywise error corrected, P < 0.05); impairment in tongue force, metronome tapping and ASE were all associated with striatal loss. Additionally, tongue force deficits and ASE were associated with volume reduction in the occipital lobe. Impaired recognition of negative emotions was associated with volumetric reductions in the precuneus and cuneus. Our study reveals specific associations between atrophy and decline in a range of clinical modalities, demonstrating the utility of VBM correlation analysis for investigating these relationships in HD.
Collapse
Affiliation(s)
- Rachael I Scahill
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Omar R, Henley SMD, Bartlett JW, Hailstone JC, Gordon E, Sauter DA, Frost C, Scott SK, Warren JD. The structural neuroanatomy of music emotion recognition: evidence from frontotemporal lobar degeneration. Neuroimage 2011; 56:1814-21. [PMID: 21385617 PMCID: PMC3092986 DOI: 10.1016/j.neuroimage.2011.03.002] [Citation(s) in RCA: 127] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2010] [Revised: 02/14/2011] [Accepted: 03/01/2011] [Indexed: 11/26/2022] Open
Abstract
Despite growing clinical and neurobiological interest in the brain mechanisms that process emotion in music, these mechanisms remain incompletely understood. Patients with frontotemporal lobar degeneration (FTLD) frequently exhibit clinical syndromes that illustrate the effects of breakdown in emotional and social functioning. Here we investigated the neuroanatomical substrate for recognition of musical emotion in a cohort of 26 patients with FTLD (16 with behavioural variant frontotemporal dementia, bvFTD, 10 with semantic dementia, SemD) using voxel-based morphometry. On neuropsychological evaluation, patients with FTLD showed deficient recognition of canonical emotions (happiness, sadness, anger and fear) from music as well as faces and voices compared with healthy control subjects. Impaired recognition of emotions from music was specifically associated with grey matter loss in a distributed cerebral network including insula, orbitofrontal cortex, anterior cingulate and medial prefrontal cortex, anterior temporal and more posterior temporal and parietal cortices, amygdala and the subcortical mesolimbic system. This network constitutes an essential brain substrate for recognition of musical emotion that overlaps with brain regions previously implicated in coding emotional value, behavioural context, conceptual knowledge and theory of mind. Musical emotion recognition may probe the interface of these processes, delineating a profile of brain damage that is essential for the abstraction of complex social emotions.
Collapse
Affiliation(s)
- Rohani Omar
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Schneider SA, Wilkinson L, Bhatia KP, Henley SMD, Rothwell JC, Tabrizi SJ, Jahanshahi M. Abnormal explicit but normal implicit sequence learning in premanifest and early Huntington's disease. Mov Disord 2010; 25:1343-9. [PMID: 20544716 DOI: 10.1002/mds.22692] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Learning may occur with or without awareness, as explicit (intentional) or implicit (incidental) learning. The caudate nucleus and the putamen, which are affected early in Huntington's disease (HD), are thought to be essential for motor sequence learning. However, the results of existing studies are inconsistent concerning presence/absence of deficits in implicit and explicit motor sequence learning in HD. We assessed implicit and explicit motor sequence learning using sequences of equivalent structure in 15 individuals with a positive HD genetic test (7 premanifest; 8 early stage disease) and 11 matched controls. The HD group showed evidence of normal implicit motor sequence learning, whereas explicit motor sequence learning was impaired in manifest and premanifest HD gene carriers, with progressive decline with progressive disease. Explicit sequence learning may be a useful cognitive biomarker for HD progression.
Collapse
Affiliation(s)
- Susanne A Schneider
- Sobell Department of Motor Neuroscience and Movement Disorders, UCL, Institute of Neurology, Queen Square,London, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
21
|
Hobbs NZ, Henley SMD, Ridgway GR, Wild EJ, Barker RA, Scahill RI, Barnes J, Fox NC, Tabrizi SJ. The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry 2010; 81:756-63. [PMID: 19955112 DOI: 10.1136/jnnp.2009.190702] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND Unbiased longitudinal studies are needed to understand the distributed neurodegenerative changes of Huntington's disease (HD). They may also provide tools for assessing disease-modifying interventions. The authors investigated the progression of regional atrophy in premanifest and early HD compared with controls. METHODS Nine controls, 17 premanifest and 21 early HD subjects underwent volumetric MRI at baseline and 2 years. Premanifest subjects were on average 18.1 years before predicted motor onset. Non-linear registration was used to model within-subject change over the scanning interval, and statistical parametric mapping was used to examine group differences and associations with clinical variables. RESULTS In early HD, increased grey-matter (GM) atrophy rates were evident throughout the subcortical GM and over selective cortical regions compared with controls. This group also demonstrated strikingly widespread increases in white-matter (WM) atrophy rates. The authors observed no significant differences between premanifest HD and controls. Longer CAG was associated with higher atrophy rates over large WM areas including brainstem and internal capsule and over small GM regions including thalamus and occipital cortex. Worse baseline motor score was associated with regionally increased rates in the thalamus, internal capsule and occipital lobe. Sample-size calculations indicate that 19 and 24 early HD subjects per treatment arm would need to complete a 2-year trial in order to detect a 50% reduction in WM and GM atrophy rates respectively. CONCLUSIONS Degeneration of structural connectivity may play an important role in early HD symptoms. Assessment of WM and GM changes will be important in understanding the complexity of HD and its treatment.
Collapse
Affiliation(s)
- Nicola Z Hobbs
- Dementia Research Centre, UCL Institute of Neurology, University College London, London, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Hobbs NZ, Barnes J, Frost C, Henley SMD, Wild EJ, Macdonald K, Barker RA, Scahill RI, Fox NC, Tabrizi SJ. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol 2010; 31:1036-41. [PMID: 20150305 DOI: 10.3174/ajnr.a2018] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Longitudinal MR imaging measures provide an opportunity to track progression in HD before the emergence of clinical symptoms. This may prove useful in assessing disease-modifying treatments. We investigated how caudate and global volumes change as HD progresses from premanifest to early disease. MATERIALS AND METHODS Forty HD gene-positive individuals and 19 controls underwent serial volumetric MR imaging (baseline, 12 and 27 months; 2 or 3 scans per person). At baseline, 3 patients with HD were premanifest but developed overt motor features during the study, and 37 had early HD. All had dates of motor onset recorded. Caudates, lateral ventricles, and TIVs were measured using semiautomated procedures. Linear mixed models were used to investigate differences between HD and controls in relation to motor onset, controlling for TIV, sex, and age. RESULTS Extrapolating backwards in time, we found that differences in caudate and ventricular volumes between patients with HD and controls were evident 14 and 5 years, respectively, before motor onset (P < .05). At onset, caudate volume was 2.58 mL smaller than that in controls (P < .0001); ventricular volume was 9.27 mL larger (P < .0001). HD caudate atrophy rates were linear, showed low variability between subjects, and were approximately 10-fold higher than those in controls (P < .001). HD ventricular enlargement rates were variable between subjects, were approximately 4-fold higher than those in controls at onset (P < .001), and accelerated with disease duration (P = .02). CONCLUSIONS We provide evidence of acceleration of global atrophy in HD with disproportionate caudate involvement. Both caudate and global measures may be of use as early markers of HD pathology.
Collapse
Affiliation(s)
- N Z Hobbs
- Dementia Research Centre and Department of Neurodegenerative Disease, Institute of Neurology, University College London, Queen Square, London, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Henley SMD, Ridgway GR, Scahill RI, Klöppel S, Tabrizi SJ, Fox NC, Kassubek J. Pitfalls in the use of voxel-based morphometry as a biomarker: examples from huntington disease. AJNR Am J Neuroradiol 2009; 31:711-9. [PMID: 20037137 DOI: 10.3174/ajnr.a1939] [Citation(s) in RCA: 79] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
BACKGROUND AND PURPOSE VBM is increasingly used in the study of neurodegeneration, and recently there has been interest in its potential as a biomarker. However, although it is largely "automated," VBM is rarely implemented consistently across studies, and changing user-specified options can alter the results in a way similar to the very biologic differences under investigation. MATERIALS AND METHODS This work uses data from patients with HD to demonstrate the effects of several user-specified VBM parameters and analyses: type and level of statistical correction, modulation, smoothing kernel size, adjustment for brain size, subgroup analysis, and software version. RESULTS The results demonstrate that changing these options can alter results in a way similar to the biologic differences under investigation. CONCLUSIONS If VBM is to be useful clinically or considered for use as a biomarker, there is a need for greater recognition of these issues and more uniformity in its application for the method to be both reproducible and valid.
Collapse
Affiliation(s)
- S M D Henley
- Dementia Research Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, United Kingdom
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Henley SMD, Wild EJ, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ. Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord 2009; 24:932-6. [PMID: 19243073 DOI: 10.1002/mds.22485] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole-brain atrophy rates over 1 year in early and premanifest HD subjects, and controls. Early HD subjects had statistically significantly (P = 0.007) increased (threefold higher) rates of whole-brain atrophy compared with controls. Higher atrophy rates were associated with longer CAG repeat length. MRI-based measures of whole-brain atrophy may have potential as a measure of progression in HD.
Collapse
Affiliation(s)
- Susie M D Henley
- Dementia Research Centre, Institute of Neurology, National Hospital for Neurology and Neurosurgery, University College London, Queen Square, London, United Kingdom.
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Hailstone JC, Omar R, Henley SMD, Frost C, Kenward MG, Warren JD. It's not what you play, it's how you play it: timbre affects perception of emotion in music. Q J Exp Psychol (Hove) 2009; 62:2141-55. [PMID: 19391047 PMCID: PMC2683716 DOI: 10.1080/17470210902765957] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Salient sensory experiences often have a strong emotional tone, but the neuropsychological relations between perceptual characteristics of sensory objects and the affective information they convey remain poorly defined. Here we addressed the relationship between sound identity and emotional information using music. In two experiments, we investigated whether perception of emotions is influenced by altering the musical instrument on which the music is played, independently of other musical features. In the first experiment, 40 novel melodies each representing one of four emotions (happiness, sadness, fear, or anger) were each recorded on four different instruments (an electronic synthesizer, a piano, a violin, and a trumpet), controlling for melody, tempo, and loudness between instruments. Healthy participants (23 young adults aged 18–30 years, 24 older adults aged 58–75 years) were asked to select which emotion they thought each musical stimulus represented in a four-alternative forced-choice task. Using a generalized linear mixed model we found a significant interaction between instrument and emotion judgement with a similar pattern in young and older adults (p < .0001 for each age group). The effect was not attributable to musical expertise. In the second experiment using the same melodies and experimental design, the interaction between timbre and perceived emotion was replicated (p < .05) in another group of young adults for novel synthetic timbres designed to incorporate timbral cues to particular emotions. Our findings show that timbre (instrument identity) independently affects the perception of emotions in music after controlling for other acoustic, cognitive, and performance factors.
Collapse
Affiliation(s)
- Julia C Hailstone
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | | | | | | | | | | |
Collapse
|
26
|
Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SMD, Hobbs NZ, Mandelli ML, Grisoli M, Björkhem I, Cattaneo E, Di Donato S. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. ACTA ACUST UNITED AC 2008; 131:2851-9. [PMID: 18772220 DOI: 10.1093/brain/awn212] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients' tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1-3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P < 0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P < 0.001). As expected, significant differences in caudate volumes between stage 1-2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease.
Collapse
Affiliation(s)
- Valerio Leoni
- Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Henley SMD, Wild EJ, Hobbs NZ, Warren JD, Frost C, Scahill RI, Ridgway GR, MacManus DG, Barker RA, Fox NC, Tabrizi SJ. Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia 2008; 46:2152-60. [PMID: 18407301 DOI: 10.1016/j.neuropsychologia.2008.02.025] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2007] [Revised: 01/04/2008] [Accepted: 02/23/2008] [Indexed: 10/22/2022]
Abstract
Huntington's disease (HD) is an inherited neurodegenerative disorder that classically presents with motor, cognitive and psychiatric symptoms. However, other abnormalities also occur in this condition, notably deficient recognition of facial emotional expressions. Deficits in emotion recognition impact significantly on the lives of HD patients and their families and thus it is important to clarify the onset and pattern of impairment. This study investigated facial emotion recognition in a large cohort of early HD patients, and premanifest gene-carriers. We used voxel-based morphometry (VBM) to examine the neuroanatomical correlates of emotion recognition performance. Forty patients with early HD, 21 premanifest gene carriers and 20 controls were assessed using 24 faces from the Ekman Pictures of Facial Affect, and volumetric brain MRI. The HD group was significantly worse than controls at recognising, surprise, disgust, anger and fear, and worse than the premanifest group at recognising disgust and anger. When patient data were expressed as z-scores, recognition of anger was significantly worse than disgust in the early HD group. In the VBM analysis, these deficits were associated with common regional atrophy: impaired recognition of surprise, disgust, anger and fear were all associated with striatal volume loss. Fear was associated with additional atrophy of the right insula and left and right lateral orbitofrontal cortex. Even in early HD there is a wide-ranging impairment in recognition of negative emotions denoting 'threat'. Our findings implicate a generic fronto-subcortical network in the pathogenesis of these emotion recognition deficits.
Collapse
Affiliation(s)
- Susie M D Henley
- Dementia Research Centre, Institute of Neurology, University College London, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Chan D, Henley SMD, Rossor MN, Warrington EK. Extensive and Temporally Ungraded Retrograde Amnesia in Encephalitis Associated With Antibodies to Voltage-Gated Potassium Channels. ACTA ACUST UNITED AC 2007; 64:404-10. [PMID: 17353384 DOI: 10.1001/archneur.64.3.404] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
BACKGROUND Encephalitis associated with antibodies to voltage-gated potassium channels (VGKC-Ab) is characterized by epilepsy, behavioral changes, and anterograde memory impairment. Magnetic resonance imaging reveals abnormal signal predominantly restricted to the mediotemporal lobes. OBJECTIVE To determine the temporal extent and potential reversibility of retrograde amnesia in 3 patients with VGKC-Ab-associated encephalitis. DESIGN Case report. SETTING Clinical. Patients Three patients diagnosed as having VGKC-Ab-associated encephalitis underwent cognitive testing before and after immunotherapy. MAIN OUTCOME MEASURES In addition to standard neuropsychological tests, retrograde memory was assessed using 2 novel tests. Memory for past newsworthy events was assessed using a public events test; test material was divided into epochs of 5 years and spanned approximately 25 years. This was complemented by a famous faces test in which patients were required to identify individuals from the recent and remote past. RESULTS All 3 patients were found to have temporally ungraded retrograde amnesia dating back more than 20 years. Magnetic resonance imaging in all patients revealed high-signal abnormalities predominantly affecting the hippocampi. Subsequent testing performed after immunotherapy revealed subjective improvement but no evidence of a temporal gradient in the recovery of past memories. CONCLUSIONS Encephalitis associated with VGKC-Ab results in extensive and temporally ungraded retrograde amnesia that is partially reversible with immunotherapy. Magnetic resonance imaging high-signal abnormalities were primarily restricted to the hippocampi. These data are supportive of theories postulating a role for the hippocampus in the storage and retrieval of all past memories, irrespective of age, rather than theories of memory consolidation that propose an involvement of the hippocampus only in the temporary storage of memories.
Collapse
Affiliation(s)
- Dennis Chan
- Department of Neurology, Royal Sussex County Hospital, Brighton, United Kingdom.
| | | | | | | |
Collapse
|
29
|
Abstract
The authors measured the rate of whole-brain atrophy over 6 months in 13 patients with early Huntington disease (HD) and seven matched controls. Patients with early HD had significantly increased rates of whole-brain atrophy vs controls (mean [SD] HD, 1.10 [0.88]%/year; controls, 0.26 [0.54]%/year). The measurement of cerebral change over short time periods (e.g., 6 months) may be relevant for trials designed to assess effects on neurodegeneration or atrophy.
Collapse
Affiliation(s)
- S M D Henley
- Dementia Research Centre, Institute of Neurology, University College London, London, UK
| | | | | | | | | | | |
Collapse
|
30
|
Abstract
PURPOSE OF REVIEW A major goal of current clinical research in neurodegenerative diseases is to improve early detection of disease and presymptomatic detection of neuronal dysfunction. We also need better tools to assess disease progression in this group of disorders. Currently, many potential disease-modifying therapies are being developed and evaluated at the preclinical stage, and will lead to clinical trials in the near future for which biomarkers are urgently needed. This review summarizes the field of biomarker research in the major neurodegenerative diseases. RECENT FINDINGS Many different approaches are being undertaken to identify biomarkers and include imaging, neurophysiological and cognitive testing in addition to newer technologies such as biochemical, proteomic, metabanomic and gene array profiling of tissue and biofluids from patients. Key recent findings in each of these areas are discussed. SUMMARY The ideal biomarker needs to be easy to quantify and measure, reproducible, not subject to wide variation in the general population and unaffected by co-morbid factors. For evaluation of therapies the biomarker needs to change linearly with disease progression and closely correlate with established clinico-pathological parameters of the disease. It is unlikely that any one biomarker will fulfil all these characteristics, and it is likely that more than one biomarker will be needed for early diagnosis and similarly for evaluation of disease progression for therapeutic trials. For example, the combination of more detailed clinical assessments encompassing specific cognitive and neurophysiological testing, in addition to imaging, biochemical and genomic profiling, is likely to be needed.
Collapse
Affiliation(s)
- Susie M D Henley
- Dementia Research Centre, Institute of Neurology, University College London, London, UK.
| | | | | |
Collapse
|